Table 2.
Direct pairwise comparisons and heterogeneity
| Comparison | Pairwise OR (95% CI) | Number of events | Number of patients | Number of studies | Heterogeneity test | |
|---|---|---|---|---|---|---|
| I 2 (%)a | p valueb | |||||
| All-cause mortality | ||||||
| IV COL vs. | ||||||
| GLY + IV COL | 1.13 (0.59–2.19) | 59 | 160 | 2 | 0.0 | 0.63 |
| IH COL + IV COL | 0.80 (0.58–1.11) | 285 | 642 | 7 | 18.2 | 0.29 |
| RIF + IV COL | 0.94 (0.57–1.56) | 119 | 252 | 2 | 0.0 | 0.47 |
| TIG | 1.73 (1.08–2.78) | 144 | 293 | 3 | 0.0 | 0.78 |
| CAR + IV COL vs. | ||||||
| SUL + IV COL | 1.59 (0.60–4.20) | 43 | 77 | 2 | 43.2 | 0.18 |
| Clinical cure | ||||||
| IV COL vs. | ||||||
| CAR + IV COL | 0.81 (0.37–1.76) | 199 | 248 | 2 | 0.0 | 0.46 |
| IH COL + IV COL | 1.60 (1.05–2.46) | 363 | 695 | 7 | 38.0 | 0.14 |
| TIG | 0.91 (0.43–1.89) | 59 | 125 | 2 | 0.0 | 0.83 |
| CAR + IV COL vs. | ||||||
| SUL + IV COL | 0.60 (0.17–2.11) | 51 | 77 | 2 | 11.3 | 0.29 |
| Microbiological eradication | ||||||
| IV COL vs. | ||||||
| IH COL + IV COL | 1.28 (0.88–1.57) | 242 | 465 | 5 | 0.0 | 0.73 |
| RIF + IV COL | 1.87 (1.13–3.10) | 138 | 252 | 2 | 0.0 | 0.90 |
| TIG | 0.45 (0.18–1.11) | 39 | 125 | 2 | 53.4 | 0.14 |
| CAR + IV COL vs. | ||||||
| SUL + IV COL | 1.36 (0.45–4.10) | 52 | 77 | 2 | 0.0 | 0.95 |
Abbreviations: CAR carbapenem (imipenem or meropenem), CI confidence interval, COL colistin, FOS fosfomycin, GLY glycopeptide (vancomycin or teicoplanin), HD high dose, IH inhaled, IV intravenous, OR odds ratio, RIF rifampin, SUL sulbactam, TIG tigecycline, vs. versus
aQuantified value of OR variation attributable to heterogeneity
b p value from Q test based on chi-square statistic